Monday, November 20, 2017
Enopace Biomedical, a developer of minimally invasive, implantable, endovascular neuromodulation therapies for heart failure patients, announced today that it has been selected by leading cardiologists and industry professionals at the annual Shark Tank Innovation Competition in 2017 as a premier medical innovation company. The vote took place at the Transcatheter Cardiovascular Therapeutics (TCT) conference, which took place from October 29 to November 2 , 2017 in Denver, Colorado . The TCT conference is the world's largest and most important educational conference for interventional cardiovascular medicine, and presents the latest advances in current therapies and clinical research.
Over 20 million patients in Europe and the US suffer from heart failure. This disease is associated with tremendous disease costs and remains the largest unmet clinical need in the area of ??cardiovascular disease. Founded by Rainbow Medical, Enopace has developed an endovascular neuromodulation technology that can increase cardiac performance by reducing stress and treating patients with heart failure.
Out of 60 companies reviewed by the TCT participants, 8 were selected to present their technologies. Of these, 3 were selected as finalists. The 3 finalists went through two days of presentations and question and answer sessions attended by a board of leading cardiologists and industry professionals. Enopace won the 2017 title as a leader in medical innovation.
"After an exhausting review process, we enthusiastically accepted this major award," said Amir Dagan , CEO of Enopace . "This is a reaffirmation of our unique and innovative approach to treating heart failure patients."
Efi Cohen Arazi , CEO of Rainbow Medical Investment Group, added, "This award is a great recognition of Enopace's technology and its approach to treating heart failure." According to Arazi , Rainbow Medical will "continue to invest in breakthrough solutions to large, unmet market needs such as Enopace's."
